Fludarabine

Lymphoid Leukemia

Dartmouth-Hitchcock Medical CenterSmall moleculePhase 4 / ApprovedDormant

BBB

73/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 58/ 100
Competitive Position: 95/ 100

Competitive context

13 Active assets in the Lymphoid Leukemia cohort.

Asset / Sponsor	Phase	Rating
Ibrutinib Loxo Oncology, Inc.	Phase 4	BBB
Busulfanum Dartmouth-Hitchcock Medical Center	Phase 4	BB
Pirtobrutinib Loxo Oncology, Inc.	Phase 3	BB
Lenalidomide University of Wisconsin, Madison	Phase 2	BB
Dexasone St. Jude Children's Research Hospital	Phase 2	BB

View all 50 →

Same molecule, other indications

Fludarabine is also rated in:

adult T-cell leukemia/lymphomaActive

BBB

Indicative · Phase 2

76 / 100

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant

BBB

Indicative · Phase 2

76 / 100

Fanconi anemiaActive

BBB

Indicative · Phase 2/3

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.